文献速递慢性肾脏病

血管生成素样蛋白3/4及其靶脂肪酶在CKD中的作用:药物靶点孟德尔随机化研究

The Role of Angiopoietin-Like Proteins 3 and 4 and Their Target Lipases in CKD: A Drug-Target Mendelian Randomization Study.
PubMed 文献 · Am J Kidney Dis · 2026-09-22

该药物靶点孟德尔随机化研究纳入2,369,738人(186,388例CKD),评估遗传代理的ANGPTL3、ANGPTL4及其靶脂肪酶与CKD风险及eGFRcr的关联,发现抑制ANGPTL3/ANGPTL4或增强脂蛋白脂肪酶与较低CKD风险和较高eGFRcr相关。

要点

  • 遗传代理抑制ANGPTL3或ANGPTL4与CKD风险降低及eGFRcr升高相关。
  • 遗传代理增强脂蛋白脂肪酶与CKD风险降低及eGFRcr升高相关。
  • ANGPTL3、ANGPTL4和LPL在肾脏细胞类型及CKD患者与对照间存在差异表达。

核心结论

  • 遗传性降低ANGPTL3和ANGPTL4通过增强脂肪酶活性降低CKD风险。
  • ANGPTL3、ANGPTL4及其靶脂肪酶(脂蛋白脂肪酶和内皮脂肪酶)是CKD防治的潜在治疗靶点。

研究设计与样本

  • 药物靶点孟德尔随机化研究及单细胞RNA测序分析。
  • 纳入欧洲、东亚和非洲 ancestry 的All of Us、Penn Medicine Biobank和GWAS参与者,共2,369,738人,其中186,388例CKD。
  • 肾脏样本来自Susztaklab Kidney Biobank。

主要发现

  • 甘油三酯每降低1 SD,遗传代理抑制ANGPTL3、抑制ANGPTL4和增强脂蛋白脂肪酶分别与较低CKD风险相关(OR 0.76 [95% CI 0.69-0.84]、0.78 [95% CI 0.68-0.91]、0.86 [95% CI 0.83-0.90])及较高eGFRcr相关。
  • 高密度脂蛋白胆固醇每降低1 SD,遗传代理增强内皮脂肪酶与欧洲 ancestry 人群较低CKD风险相关(OR 0.89 [95% CI 0.82-0.96])及较高eGFRcr相关。
  • 遗传代理增强肝脂肪酶与非洲 ancestry 人群较低CKD风险相关(OR 0.83 [95% CI 0.74-0.92])。
  • ANGPTL3、ANGPTL4和LPL在肾脏细胞类型间及CKD患者与对照间存在差异表达。

临床怎么用

  • ANGPTL3、ANGPTL4及其靶脂肪酶可作为CKD预防和治疗的潜在药物靶点进行进一步临床研究。

局限性

  • 孟德尔随机化严格假设的限制。
  • 工具变量选择非肾脏特异性。
  • CKD可能存在潜在错误分类。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Angiopoietin-like proteins (ANGPTL) 3 and 4 modulate lipoprotein metabolism through inhibition of lipases. Reduced activity of ANGPTL3 and ANGPTL4 improves kidney function in mice. This study investigated the causal relationships of ANGPTLs and their lipase targets with chronic kidney disease (CKD) in humans. STUDY DESIGN: A drug-target Mendelian randomization (MR) study and single-cell RNA sequencing analyses. SETTING & PARTICIPANTS: Participants of European, East Asian, and African ancestry in the All of Us, Penn Medicine Biobank, and genome-wide association studies; kidney samples from the Susztaklab Kidney Biobank. EXPOSURE: Genetically proxied ANGPTL3, ANGPTL4, lipoprotein lipase, endothelial lipase, and hepatic lipase. OUTCOME: CKD risk and estimated glomerular filtration rate based on serum creatinine (eGFRcr). ANALYTICAL APPROACH: Genetic variants were used as proxies for ANGPTLs and their lipase targets, and their associations with CKD risk and eGFRcr were assessed. Relevant gene expression across kidney cell types and between CKD patients and controls was also characterized. RESULTS: In total, 186,388 CKD cases among 2,369,738 individuals were included. For each 1 SD decrease in triglycerides, genetically proxied ANGPTL3 inhibition, ANGPTL4 inhibition, and lipoprotein lipase enhancement were associated with lower CKD risk (odds ratio [OR], 0.76 [95% CI, 0.69-0.84], 0.78 [95% CI, 0.68-0.91], and 0.86 [95% CI, 0.83-0.90]) and higher eGFRcr. For each 1 SD decrease in high-density lipoprotein cholesterol, genetically proxied endothelial lipase enhancement was associated with lower CKD risk (OR, 0.89 [95% CI, 0.82-0.96]) and higher eGFRcr specifically in people of European ancestry. Genetically proxied hepatic lipase enhancement was associated with lower CKD risk (OR, 0.83 [95% CI, 0.74-0.92]) specifically in people of African ancestry. ANGPTL3, ANGPTL4, and LPL were differentially expressed across kidney cell types and between CKD patients and controls. LIMITATIONS: Rigorous MR assumptions, non-kidney-specific instrument selection, and potential misclassification of CKD. CONCLUSIONS: Genetic reductions in ANGPTL3 and ANGPTL4 reduce CKD risk by enhancing lipase activity. ANGPTL3, ANGPTL4, and their target lipases (lipoprotein lipase and endothelial lipase) are potentially promising therapeutic targets for CKD prevention and treatment. PLAIN-LANGUAGE SUMMARY: Angiopoietin-like proteins (ANGPTL) 3 and 4 modulate blood lipid levels by inhibiting lipase activity. This study investigated whether ANGPTL3 and 4 and their lipase targets affect chronic kidney disease (CKD). It used genetic variants as proxies for ANGPTL3 and 4 and for their target lipases and assessed their associations with CKD risk and kidney function in over 2.3 million individuals. It found that genetic proxies for inhibition of ANGPTL3 and 4, as well as for enhanced activity of lipoprotein lipase and endothelial lipase, were associated with lower risk of CKD and better kidney function. This study suggests that these proteins and lipases are potentially promising therapeutic targets for CKD prevention and treatment.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Yang G, Zhang DY, Fischman CJ, et al. The Role of Angiopoietin-Like Proteins 3 and 4 and Their Target Lipases in CKD: A Drug-Target Mendelian Randomization Study. Am J Kidney Dis. 2026. PMID: 42772348. doi:10.1053/j.ajkd.2026.06.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。